Results 71 to 80 of about 408 (149)
Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution [PDF]
, 2014 Cytokine therapy can activate potent, sustained antitumor responses, but collateral toxicity often limits dosages. Although antibody–cytokine fusions (immunocytokines) have been designed with the intent to localize cytokine activity, systemic dose ...
Tzeng, Alice +4 more
core +1 more source
, 2022 Tumor-targeting antibody (Ab)-fused cytokines, referred to as immunocytokines, are designed to increase antitumor efficacy and reduce toxicity through the tumor-directed delivery of cytokines.
Jung-Eun Kim (83763) +4 more
core +1 more source
DEVELOPMENT OF NOVEL ANTI-CANCER BIOTHERAPEUTICS: FROM THE BENCH TO THE CLINIC
, 2020 Cytokines have a potent therapeutic activity in malignances. However, their use in cancer immunotherapy is limited by their inability to determine optimal concentrations into tumor sites due to dose-limiting systematic toxicities.
Rondinini, Chiara
core +1 more source
Cancer is a leading cause of death worldwide. Although many treatments are available, immunotherapy has recently expanded the therapeutic options by stimulating the patient’s own immune system to kill tumor cells. One form of immunotherapy is antibody therapy. Antibodies can directly inhibit tumor growth or indirectly recruit immune cells to kill tumor
openaire +2 more sources
Citation: 'immunocytokine' in the IUPAC Compendium of Chemical Terminology, 5th ed.; International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.13280 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms.
openaire +1 more source
The immunocytokine NHS-IL12 as a potential cancer therapeutic
Oncotarget, 2014 Targeted delivery of IL-12 might turn this cytokine into a safer, more effective cancer therapeutic. Here we describe a novel immunocytokine, NHS-IL12, consisting of two molecules of IL-12 fused to a tumor necrosis-targeting human IgG1 (NHS76). The addition of the human IgG1 moiety resulted in a longer plasma half-life of NHS-IL12 than recombinant IL ...
Jonathan, Fallon +9 more
openaire +3 more sources
Imaging–guided optimization of biodistribution and antitumor efficacy of L19-based immunocytokines
Translational OncologyAntibody-based targeted delivery of pharmaceuticals is an attractive approach to preferentially localize anti-cancer payloads to neoplastic lesions. The L19 antibody, specific for the extra domain B of fibronectin, is used in several antibody-cytokine ...
Tommaso Virgilio +12 more
doaj +1 more source
, 2016 Multifunctional antibody-based biologics, such as bispecific antibodies and immunocytokines, can be difficult to produce with sufficient yield and stability, and often exhibit inferior pharmacokinetics.
Thomas M. Cardillo (139396) +3 more
core +1 more source
Radiotherapy in Combination With Cytokine Treatment
Frontiers in Oncology, 2019 Radiotherapy (RT) plays an important role in the management of cancer patients. RT is used in more than 50% of patients during the course of their disease in a curative or palliative setting.
Ondrej Palata +12 more
doaj +1 more source
Journal for ImmunoTherapy of CancerBackground SOT201 and its murine surrogate mSOT201 are novel cis-acting immunocytokines consisting of a humanized/murinized/, Fc-silenced anti-programmed cell death protein 1 (PD-1) monoclonal antibody (mAb) fused to an attenuated human interleukin (IL ...
Ulrich Moebius +26 more
doaj +1 more source